Latest Earnings Results: Q3 '26
Estimated EPS
$3.73
Reported EPS
$3.82
Surprise
+2.51%
Estimated Rev
$17.32B
Reported Rev
$17.4B
Surprise
+0.51%
• Reported GAAP EPS of $3.82 up 105.38% YoY • Reported revenue of $17.4B up 10.32% YoY • AbbVie raised 2026 adjusted diluted EPS guidance from $13.76 - $13.96 to $13.95 - $13.99, including an unfavorable $0.69 per share impact related to acquired IPR&D and milestones expense incurred year-to-date through Q3 2026.
Bullish Takeaway
AbbVie recorded growth in immunology and neuroscience revenues, completed the Apogee acquisition to deepen its immunology pipeline, and reported FDA approval of Skyrizi subcutaneous induction for Crohn's disease.
Bearish Takeaway
AbbVie reported lower Humira and Imbruvica revenues, oncology revenue growth of 0.8%, declining aesthetics and Juvederm revenues, and identified competition, research and development, and drug-pricing risks.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | $3.91 | -- | -- | N/A |
Q3 '26 | $3.73 | $3.82 | 2.51% | BEAT |
Q2 '26 | $3.60 | $3.65 | 1.40% | BEAT |
Q1 '26 | $2.59 | $2.65 | 2.23% | BEAT |
Q4 '25 | $2.65 | $2.71 | 2.15% | BEAT |